Cellular reprogramming: a model for melanoma cellular plasticity

Cellular plasticity of cancer cells is often associated with phenotypic heterogeneity and drug resistance and thus remains a major challenge for the treatment of melanoma and other types of cancer. Melanoma cells have the capacity to switch their phenotype during tumor progression, from a proliferat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Granados, Karol (VerfasserIn) , Poelchen, Juliane (VerfasserIn) , Novak, Daniel (VerfasserIn) , Utikal, Jochen (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 5 November 2020
In: International journal of molecular sciences
Year: 2020, Jahrgang: 21, Heft: 21, Pages: 1-14
ISSN:1422-0067
DOI:10.3390/ijms21218274
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.3390/ijms21218274
Verlag, kostenfrei, Volltext: https://www.mdpi.com/1422-0067/21/21/8274
Volltext
Verfasserangaben:Karol Granados, Juliane Poelchen, Daniel Novak and Jochen Utikal
Beschreibung
Zusammenfassung:Cellular plasticity of cancer cells is often associated with phenotypic heterogeneity and drug resistance and thus remains a major challenge for the treatment of melanoma and other types of cancer. Melanoma cells have the capacity to switch their phenotype during tumor progression, from a proliferative and differentiated phenotype to a more invasive and dedifferentiated phenotype. However, the molecular mechanisms driving this phenotype switch are not yet fully understood. Considering that cellular heterogeneity within the tumor contributes to the high plasticity typically observed in melanoma, it is crucial to generate suitable models to investigate this phenomenon in detail. Here, we discuss the use of complete and partial reprogramming into induced pluripotent cancer (iPC) cells as a tool to obtain new insights into melanoma cellular plasticity. We consider this a relevant topic due to the high plasticity of melanoma cells and its association with a strong resistance to standard anticancer treatments.
Beschreibung:Gesehen am 29.07.2024
Beschreibung:Online Resource
ISSN:1422-0067
DOI:10.3390/ijms21218274